

Corona Pharmaceuticals

[View the current Corona Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/2995-Corona+Pharmaceuticals.html)

(<http://www.bioportfolio.com/bioporporate/2995-Corona+Pharmaceuticals.html>)

Contact Details:

100 West 73 St. Apt. 3A
 New York City
 NY
 10023
 United States of America

Tel: 800 531 1884
 Fax: 212 877 6694
 Email:

Press Releases on Corona Pharmaceuticals:

"As an Industry, We've Been too Focused on Regulatory Approval." Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.	26th November, 2009		<i>LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes</i>
Onyx Pharmaceuticals Announces December 2009 Investor Events	25th November, 2009	Onyx Pharmaceuticals, Inc.	<i>EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, SAN DIEGO, Nov. 25</i>
Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference	25th November, 2009	Ardea Biosciences, Inc.	<i>/PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper</i>

[iThemba Pharmaceuticals \(Pty\) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering](#) 25th November, 2009

DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals's service division and Pyxis Discovery announced today that they have signed a collaborative agreement

[Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective](#) 25th November, 2009 Reportlinker

NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective <http://www>

BioNews Results for Corona Pharmaceuticals



- [Corona-based Watson Pharmaceuticals announces \\$63 million profit](#)
Individual.com: Nov 5 2009 11:54PM Matching: corona pharmaceuticals
- [Corona-based Watson Pharmaceuticals announces \\$63 million profit \[The Press-Enterprise, Riverside, Calif.\]](#)
Therapeutics Daily: Nov 5 2009 10:41PM Matching: corona pharmaceuticals
- [Corona-based Watson Pharmaceuticals announces \\$63 million profit](#)
Riverside Press Enterprise: Nov 5 2009 7:58AM Matching: corona pharmaceuticals
- [Watson Pharma Q3 Profit Falls; Adj. EPS Rises, Tops View - Update](#)
Quote.com Japan: Nov 4 2009 10:45PM Matching: corona pharmaceuticals
- [Watson and Barr Settle Laws](#)
Intellectual Property News Agency: Nov 2 2009 11:06AM Matching: corona pharmaceuticals
- [Watson and Barr Settle Lawsuit Over Oxytrol](#)
Pharma Live: Oct 30 2009 1:17PM Matching: corona pharmaceuticals
- [Watson and Barr Settle Lawsuit Over Oxytrol](#)
Intellectual Property News Agency: Oct 29 2009 8:27AM Matching: corona pharmaceuticals
- [Watson and Barr Settle Lawsuit Over Oxytrol](#)
Pharmaceutical Online: Oct 29 2009 12:22PM Matching: corona pharmaceuticals
- [Watson and Barr Settle Lawsuit Over Oxytrol\(R\)](#)
Denver Business Journal: Oct 28 2009 12:57PM Matching: corona pharmaceuticals
- [Watson and Barr Settle Lawsuit Over Oxytrol\(R\)](#)
Washington Business Journal: Oct 28 2009 12:48PM Matching: corona pharmaceuticals
- [Watson and Barr Settle Lawsuit Over Oxytrol\(R\)](#)
Puget Sound Business Journal: Oct 28 2009 12:34PM Matching: corona pharmaceuticals
- [Watson and Barr Settle Lawsuit Over Oxytrol\(R\)](#)
Birmingham Business Journal: Oct 28 2009 12:28PM Matching: corona pharmaceuticals
- [Watson and Barr Settle Lawsuit Over Oxytrol\(R\)](#)
Stockwatch: Oct 28 2009 12:13PM Matching: corona pharmaceuticals

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

